Kymera Therapeutics
Logotype for Kymera Therapeutics Inc

Kymera Therapeutics (KYMR) investor relations material

Kymera Therapeutics Q3 2026 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Kymera Therapeutics Inc
Q3 2026 earnings summary29 Oct, 2026

Executive summary

  • KT-579 Phase 1 showed ≥90% median IRF5 degradation across multiple-dose cohorts, broad biomarker modulation across immune pathways and placebo-comparable safety.

  • KT-621 is in Phase 2b trials for atopic dermatitis and asthma; KT-579’s LUMORA lupus Phase 1b study is planned for early 2027.

Financial highlights

  • Q3 collaboration revenue was $0, versus $2.764M in Q3 2025; no additional collaboration revenue is expected in 2026.

  • Q3 R&D expense was $128.509M versus $74.094M; G&A was $18.7M versus $17.3M.

  • Q3 net loss was $131.999M versus $82.175M; diluted loss per share was $1.32 versus $0.94.

  • Nine-month collaboration revenue was $99.365M versus $36.341M; net loss was $262.444M versus $224.370M.

  • Q3 adjusted cash R&D was $117.6M, up 8% QoQ; adjusted cash G&A was $10.8M, down 14% QoQ.

Outlook and guidance

  • KT-621 BROADEN2 atopic dermatitis results are expected by year-end 2026; the first AD Phase 3 trial is targeted for mid-2027, subject to supportive results and FDA alignment.

  • KT-621 BREADTH asthma Phase 2b results are expected in late 2027; KT-579 LUMORA lupus trial start is planned by early 2027.

  • KT-200 IND filing is targeted for 2027; Gilead is conducting IND-enabling studies.

  • Cash and securities of $1,645.883M at September 30, 2026 are expected to fund operations into 2029; R&D and G&A are expected to rise as development advances.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Kymera Therapeutics earnings date

Logotype for Kymera Therapeutics Inc
Study result23 Nov, 2026
Kymera Therapeutics
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Kymera Therapeutics earnings date

Logotype for Kymera Therapeutics Inc
Study result23 Nov, 2026

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Kymera Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing targeted protein degradation therapies. The company’s proprietary platform aims to design small-molecule drugs that selectively degrade disease-causing proteins, offering a novel approach to treating conditions that have been difficult to address with traditional therapies. Kymera Therapeutics is engaged in research and development across various therapeutic areas, including oncology, immunology, and inflammation. The company is headquartered in Watertown, United States, and its shares are listed on the NASDAQ.